Recent Updates
Recently added Catalysts
LUCD Positive Sentiment

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Key Takeaway: Lucid Diagnostics Inc. will host a business update conference call and webcast on August 13, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations, growth strategy, and second quarter financial results. The event aims to provide investors with insights into the company's performance and future direction.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is actively engaging with investors through a conference call.
  • The company is focused on cancer prevention, addressing a significant health issue.
  • Leadership will discuss growth strategies and financial results, indicating transparency.

Full Press Release Details

Conference Call and Webcast at 8:30 AM ET
NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2026 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Frequently Asked Questions

When is the Lucid Diagnostics Q2 2026 update call?

The update call is scheduled for August 13, 2026, at 8:30 AM ET.

Who will speak during the conference call?

CEO Lishan Aklog and CFO Dennis McGrath will provide updates.

How can I access the conference call?

Listeners can join by phone or via the webcast on Lucid's website.

What is the focus of Lucid Diagnostics?

Lucid focuses on cancer prevention, particularly for patients at risk of esophageal cancer.

Last updated: Jul 30, 2026